GILEAD SCIENCES, INC.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

GILD$169.32+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Year Ended December 31,
(in millions, except per share amounts)	2025	2024	2023
Revenues:
Product sales	$28,915	$28,610	$26,934
Royalty, contract and other revenues	527	144	182
Total revenues	29,443	28,754	27,116
Costs and expenses:
Cost of goods sold	6,234	6,251	6,498
Research and development expenses	5,799	5,907	5,718
Acquired in-process research and development expenses	1,024	4,663	1,155
In-process research and development impairments	590	4,180	50
Selling, general and administrative expenses	5,774	6,091	6,090
Total costs and expenses	19,421	27,092	19,511
Operating income	10,022	1,662	7,605
Interest expense	1,024	977	944
Other (income) expense, net	(798)	(6)	(198)
Income before income taxes	9,796	690	6,859
Income tax expense	1,286	211	1,247
Net income	8,510	480	5,613
Net loss attributable to noncontrolling interest	—	—	(52)
Net income attributable to Gilead	$8,510	$480	$5,665
Basic earnings per share attributable to Gilead	$6.84	$0.38	$4.54
Diluted earnings per share attributable to Gilead	$6.78	$0.38	$4.50
Shares used in basic earnings per share attributable to Gilead calculation	1,244	1,247	1,248
Shares used in diluted earnings per share attributable to Gilead calculation	1,255	1,255	1,258

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.